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Postbinding defects of insulin action in human adipocytes from uremic
patients. It is now well established that longstanding human uremia is
associated with impaired in vivo insulin action on glucose utilization of
peripheral target tissues. In an attempt to define the cellular basis of the
uremic insulin resistance we studied insulin action in adipocytes from
eight patients with undialyzed chronic uremia and from eight matched
healthy controls. ('251)-Insulin binding to fat cells from uremic patients
was normal. In contrast ('4C)-D-glucose transport exhibited decreased
sensitivity to insulin. The concentrations of insulin that elicited half-
maximal response was 422 95 pmoles/liter in uremic patients and 179
38 pmoles/liter in normal subjects (P < 0.01).The noninsulin- and the
maximal insulin-stimulated glucose transport of adipocytes from uremic
patients was normal. ('4C)-D-glucose conversion to total lipids was also
measured in these cells in the absence and presence of various insulin
concentrations. Similar to the findings in transport studies the
lipogenesis of fat cells from uremic patients had depressed sensitivity to
insulin (half-maximal stimulation at 38 8 pmolesfliter in uremic
patients and at 11 3 pmoles/liter in normal subjects, P < 0.01) with
unchanged noninsulin and maximal insulin-stimulated lipogenesis.
Taken together these results suggest that the insulin resistance of
adipocytes from patients with chronic uremia may be accounted for
primarily by postbinding defects localized to glucose transport and
metabolism.
Anomalies de l'action de l'insuline en aval de Ia liaison dans des
adipocytes humains provenant de malades en urémie. II est maintenant
bien établi que l'urémie humaine au long cours s'associe a une
alteration de l'action in vivo de l'insuline sur l'utilisation du glucose par
les tissus cibles periphériques. Dans une tentative de définir Ia base
cellulaire de Ia résistance urémique a l'insuline, nous avons étudié
l'action de l'insuline dans les adipocytes de huit malades en urémie
chronique, non dialyses, et de huit contrOles sains appariés. La liaison
de 1 '('231)-insuline a des adipocytes de malades urémiques était nor-
male, A l'opposé, Ic transport du ('4C)-D-glucose presentait une
sensibilitd a l'insuline diminuée. Les concentrations d'insuline entrain-
ant la moitié de la réponse maximale dtaient de 422 95 pmoles/litre
chez les malades uremiques, et 179 38 pmoles/litre chez les normaux
(P < 0,01). Le transport de glucose maximum stimulé par l'insuline ou
non stimulé par l'insuline d'apidocytes d'urdmiques était normal. La
conversion du ('4C)-D-glucose en lipides a été aussi mesurée dans ces
cellules, en l'absence ou en presence de concentrations varides
d'insuline. Comme pour les résultats des etudes de transport, la
lipogenese des cellules graisseuses des malades urémiques avait une
sensibilité diminuée a l'insuline (stimulation demi-maximale pour 38
8 pmoles/litre chez les malades urémiques, et pour 11 3 pmoles/litre
chez les normaux P < 0,01), avec une lipogenése non insulinique ou
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stimulde au maximum par l'insuline inchangée. Pris dans leur ensemble,
ces résultats suggèrent que la résistance a l'insuline d'adipoeytes de
malades en urémie chronique pourrait étre due primitivement a des
anomalies en aval de Ia liaison, au niveau du transport et du
métabolisme du glucose.
Chronic uremia is often associated with carbohydrate intoler-
ance [1]. In studies using glucose tolerance tests or the glucose
clamp technique, it has been shown that endogenous insulin
secretion is normal in most cases of chronic uremia [1, 2].
Numerous experiments based on the forearm technique, intra-
venous insulin or tolbutamide tests [for review, see 1, 3—5] and
the euglycemic clamp technique [6, 7] demonstrate that the
glucose intolerance of uremic patients is due primarily to insulin
resistance of peripheral tissues. Moreover, studies of the in
vivo turnover of tritiated glucose have shown that the liver of
uremic humans retains normal sensitivity to insulin at least with
respect to the inhibitory effect on hepatic glucose release [6, 7].
The purpose of our present study was to define and examine
the cellular mechanisms behind the insulin resistance of periph-
eral tissue from uremic humans. In so doing, we measured
('25-I)-insulin binding and noninsulin and insulin-stimulated
(14-C)-D-glucose transport and metabolism in isolated human
adipocytes from healthy control subjects and from uremic
patients not yet on chronic dialysis treatment.
Methods
Subjects
Eight adult, ambulatory nondiabetic uremic patients were
studied and compared with sex-, age-, and weight-matched
healthy volunteers. Pertinent clinical data for the patients
appear in Table I. All patients with uremia exhibited significant
in vivo insulin resistance of glucose uptake into peripheral
tissue as judged by studies using the euglycemic clamp at
several steady-state plasma insulin concentrations (unpublished
data). None of the patients presented gastrointestinal symptoms
or clinical evidence of malnutrition. The patients were taking
the following medication: beta-adrenergic blockers (patients
numbered 2, 5, 6, and 8), hydralazine (patient 2), NaHCO3
(patient 3), NaCl (patient 4), and 1,25 dihydrocholecalciferol
(patient 8). No medication was given for the last 36 hr before the
examination. All patients performed an oral glucose tolerance
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Table 1. Clinical and laboratory data of patients
781
Patient Age Obesity
Plasma Serum
Insulin Glucose Creatinine Urea Total CO2
no. Sex years index Renal disease U/m1 mmoles/liter umoles/1iter mmoleslliter mmoles/liter
1 M 52 1.04 Chronic glomerulonephritis 19 6.5 884 38.6 15
2 M 53 0.94 Polycystic kidney disease 8 4.2 887 28.5 15
3 F 55 1.00 Polycystic kidney disease 11 5.1 766 30.6 19
4 M 58 0.97 Chronic interstitial
nephritis (analgesic) 22 4.8 929 18.7 16
5
6
F
F
55
31
0.92
0.94
Chronic interstitial
nephritis (analgesic)
Chronic glomerulonephritis
12
13
4.6
4.6
678
833
46.2
23.6
25
17
7
8
F
M
48
43
1.35
1.15
Chronic interstitial
nephntis (not classified)
Chronic glomerulonephritis
15
11
4.8
5.3
808
559
20.8
18.8
20
22
Mean 49 1.04 14 5.0 793 28.2 19
SEM 0.2 0.05 2 0.2 55 3.6 1
Table 2. Average daily intake (mean I sEM) of energy and nutrients
during the last 3 days before the study
Uremic
patients
Normal
subjects
Energy, kj 6863 7068 669
Digestible carbohydrate, g 181 17
(44 energy%)
175 13
(40 energy%)
Nondigestible carbohydrate, g 23 2 21 2
Protein, g 48 5
(12 energy%)
71 6
(16 energy%)
Fat,g 80± 11
(44 energy%)
87± 9
(44 energy%)
test (1 g of glucose/kg body wt). Patient 2 had a 2-hr value of
plasma glucose at 11.6 mmoles/liter and patient 7 had a 2-hr
value at 9.8 mmoles/liter, whereas the rest of the group all had
2-hr values below 7.5 mmoles/liter.
Four healthy males and four healthy females served as
control subjects with a mean age of 44 years (range, 58 to 26
years) while the mean obesity index was 1.05 (range, 0.85 to
1.15). In normal subjects the average fasting plasma concentra-
tions of glucose and insulin were 4.8 mmoles/liter (range, 4.2 to
5.4) and 10 jsU/ml (2 to 18), respectively. Each participant in the
study recorded the daily intake of all food and drink 3 days
before the investigation. The dietary composition was calcu-
lated according to dietary tables, and the average results are
given in Table 2. Informed consent was obtained from all
subjects after the purpose and the potential risks of the study
were explained carefully. The study protocol was approved by
the local ethical committee. All tests were performed in the
postabsorptive state at 7 A.M. following a 12-hr overnight fast.
Chemicals
Human albumin was obtained from Behringswerke, Marburg,
West Germany. Collagenase from Clostridium histolyticum,
213 U/mg was obtained from Worthington Biochemical Corpo-
ration (Freehold, New Jersey, USA). (125J) Monoiodoinsulin
with the labeled iodine in tyrosine A14 (sp act about 250 jsCi/sg)
was donated generously by NOVO Research Institute, Copen-
hagen, Denmark. D-U-('4C) glucose (sp act 284 pCi/mmoles)
were obtained from the Radiochemical Centre, Amersham,
England. Tissue and cells were suspended in Hepes buffer (10
mmoles/iiter, pH 7.4 at 37°C) [81.
Insulin receptor binding
Adipose tissue samples (about 10 g) were obtained by open
biopsy from the upper one-fourth of the right gluteal region after
a square field had been anesthetized with an epidermal injection
of 1% lidocaine without epinephrine. Details concerning fat cell
isolation as well as the determination of fat cell size and number
have been published previously [8]. The mean fat cell diameter
was 91 11 sm in uremic patients and 95 12 im in control
subjects (? > 0.1). Insulin binding to fat cells (about io cells/mi
of cell suspension) was measured in a Hepes buffer at 37°C,
after a 60-mm incubation with tyrosine-A14-labeled (125J) insulin
with or without increasing concentrations of unlabeled insulin
[8]. Cell-associated radioactivity in the presence of 100
moles/liter unlabeled insulin (nonspecific binding) averaged
2% of the total binding. Specific insulin binding to adipocytes
was expressed per 30 cm2 of surface area per milliliter.
Glucose transport
The initial glucose transport rate was measured by a modifi-
cation of our previously described method [9]. All studies were
carried out at 37°C. Adipocyte suspension (40 p1) with a volume
fraction of 0.4 (about 6 x l0 cells/mi) were placed in polypro-
pylene tubes and preincubated with or without insulin for 45
mm. Tracer D-U-('4C)-glucose [12 p1 (0.24 sCi); final glucose
concentration 20 p.moles/iiter] was added at time zero and
uptake was determined after 10 sec by adding 3 ml of phloretin
(0.3 mmoles/liter). Silicone oil (0.8 ml, 0.99 g/ml) was layered on
the top, and the tubes were spun within 2 mm at x2500g. Cells
were collected from the top of the oil and placed in scintillation
vials with 5 ml of scintillation fluid. Extracellular trapped
radioactivity was estimated by adding phloretin before the
tracer. All values were corrected for extracellular trapped
radioactivity which averaged 25% of the tracer glucose uptake
after 10 sec in the absence of insulin. The initial uptake of tracer
glucose (20 iimoles/liter) is linear from 2.5 sec to 5 mm [10]. The
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Fig. 1. Insulin binding to fat cells. Adipocytes from eight uremic
patients (s) and eight normal subjects (0) were incubated with 15
pmoles/liter ('251)-insulin at 37°C for 1 hr in the absence or presence of
unlabeled insulin at the indicated concentrations (mean I SEM).
coefficientof variation for uptake of ('4C)-D-U-glucose was 0.09
after 10 sec.
Lipo genesis
Lipogenesis was measured as the conversion of D-U-('4C)
glucose to ('4C)-total lipids [11]. Isolated adipocytes (about 7 x
i04 cells/mi) were prepared in a 10 mmoles/liter Hepes buffer
containing 0.5 mmoles/liter glucose. The cells were preincu-
bated for 45 mm at 37°C with or without insulin in increasing
concentrations. Then 0.4 Ci D-U-(14C) glucose was added to
each tube (final glucose concentration; 0.5 mmoles/Iiter) and the
incubation was continued for 90 mm followed by the addition of
H2S04. A Dole extraction was also performed [111. A sample
for liquid scintillation counting was taken from the upper phase.
(14C)-labeled total lipids were present in an average amount of
16% of the noninsulin-stimulated lipogenesis when incubations
were performed in the absence of fat cells (blank values). All
values for the fat cell producing total lipids were corrected for
the individual blank value.
Analytical methods
Plasma glucose was analyzed with a glucose dehydrogenase
method (Merck enzymatic kit). Plasma insulin was measured
with a RIA technique [12].
Statistical methods
In the text, table and figure data are given as the mean I
SEM. Significant differences between the groups were assessed
by the Mann Whitney test. In correlation studies the Spearman
test was used.
Results
The uremic condition did not influence the binding of (I25I)
insulin or the ability of unlabeled insulin to compete for the
binding over a concentration range of 0.05 to 245 nmoles/liter
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Fig. 2. Glucose transport of fat cells. Upper panel: Adipocytes from
eight uremic patients (•) and eight normal subjects (a) were preincu-
bated with or without insulin for 45 mm at 37°C. The initial transport
rate was then measured during the first 10 sec after (14C)-D-glucose had
been added to reach a final concentration of 20 tmoles/liter (mean 1
sEM). Lower panel: Glucose transport data are expressed as the
percentage of the response to insulin in maximally effective
concentrations.
(Fig. 1). Scatchard analysis (not shown) of competitive binding
data did not show apparent differences in the affinity or the
number of receptors per adipocyte between uremic and control
subjects. There were no significant correlations between insulin
binding variables and the fasting plasma (or serum) concentra-
tions of insulin, creatinine, urea or carbon dioxide.
When ('4C)-D-glucose transport was measured in the absence
or the presence of maximally effective insulin concentration
adipocytes from uremic patients responded similarly to
adipocytes from healthy volunteers (Fig. 2). However, the
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pmoles/liter in normal subjects, P < 0.01). No significant
correlations could be found between values of noninsulin
stimulated, half-maximal stimulated and maximal insulin-stim-
ulated glucose transport or metabolism and fasting plasma
(serum) concentrations of insulin, creatinine, urea, or carbon
dioxide.
Discussion
Our present report provides evidence of the cellular mecha-
nisms underlying the insulin resistance of glucose utilization of
peripheral tissue in patients with chronic renal disease. We are
well aware that adipose tissue is not the major organ among
peripheral tissues with respect to insulin-enhanced glucose
removal [13]. Adipocytes are, however, peripherally fixed cells
which are accessible for in vitro studies of insulin binding and
postbinding events [14]. Our results indicate that long-term
uremia has no significant impact on adipocyte insulin receptor
binding. Previous investigations of blood cell insulin receptors
. in human uremia have shown normal monocyte binding andio decreased or normal erythrocyte binding [7, 15—18]. Addition-
ally, studies of adipocyte insulin binding from uremic rats [19,
20] are consistent with our finding in humans. Taken together,
the available literature suggests that the insulin resistance in
human uremia does occur in the absence of altered insulin
receptor binding.
Uremic defects in adipocyte insulin action were found in the
insulin-dose response studies of glucose transport as well as
glucose metabolism. Both cellular functions were in uremic
cells characterized by impaired sensitivity to submaximal insu-
un stimulation but unaltered basal and maximal responses.
Whether the depressed insulin sensitivity of lipogenesis in
uremia represents intracellular defects of glucose metabolism
per se or is secondary to the impaired glucose transport cannot
be decided from the present study.
In comparison, studies of adipocytes from uremic rats have
shown that acute (24 hr) uremia [19] has no effect on noninsulin-
or insulin-enhanced glucose oxidation whereas chronic uremia
(14 days) caused a significant decrease of basal and maximal
glucose transport and metabolism [20]. In both studies the
sensitivity of the measured pathways to insulin was unaffected
compared with the normal state. The disparity between the
study by Maloff, McCaleb, and Lockwood [20] and the present
investigation obviously may be related to the different protocols
(species, degree and duration of uremia, and so forth).
The regulatory mediator(s) of cellular insulin resistance in
uremia is unknown and in our study we failed to show any
correlation between insulin concentrations causing half-maxi-
mal responses of glucose transport or metabolism and plasma
(serum) insulin, creatinine, urea, or carbon dioxide. Recent
studies in animals suggest, however, that the altered post-
binding effects of insulin in uremia may in part arise from
circulating factors not yet identified [20, 21].
The in vivo studies of the insulin resistance of human uremia
using the euglycemic clamp technique at more steady-state
plasma insulin levels have demonstrated both a rightward shift
of insulin dose-response curves and a decreased maximal
insulin responsiveness of the glucose disposal to peripheral
tissues [6, 7]. Under the insulin clamp study conditions the
major site of glucose uptake is muscle. Unfortunately, there is
no available technique which allows measurement of cellular
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Fig. 3. Lipogenesis of fat cells. Upper panel: Adipocytes from eight
uremic patients (•) and eight normal subjects (0) were preincubated
with or without insulin in the indicated concentrations for 45 mm at
37°C. Then ('4C)-D-glucose was added (total glucose concentration in
the final preparation was 0.5 mmoles/liter) and the incubation was
terminated after 90 mm (mean 1 SaM). Lower panel: Lipogenesis data
are expressed as the percentage of the response to insulin in maximally
effective concentrations.
insulin-dose response relationship of glucose transport was
altered by uremia. In patients with renal failure the dose-
response curve for insulin-stimulated glucose uptake was
shifted markedly to the right (Fig. 2) suggesting an impaired
sensitivity to insulin. For example, the concentrations of insulin
that elicited half-maximal effect were 422 95 pmoles/liter in
uremic patients and 179 38 pmoles/liter in healthy subjects (P
<0.01).
The effect of uremia on glucose metabolism by human
adipocytes was studied by measuring ('4C)-D-glucose conver-
sion to total lipids (Fig. 3). Both noninsulin- and maximal
insulin-stimulated lipogenesis were normal in uremic cells.
However, consistent with our observations in glucose transport
studies, the insulin concentrations giving half-maximal lipogen-
esis were significantly higher in adipocytes from uremic patients
(38 8 pmoles/liter in uremic patients versus 11 3
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insulin action in human muscle, but, provided our finding of
normal adipocyte insulin receptor binding can be extrapolated
to muscles, the clamp results are most compatible with
postbinding defects in insulin mediated in vivo glucose utiliza-
tion. Finally, because we could not find depression of maximal
idipocyte glucose metabolism in vitro, the in vivo finding of
impaired maximal responsiveness of the glucose disposal [6, 71
may reflect additional defective postbinding steps of insulin
iction in skeletal muscles.
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